Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and... Read More

Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY4302814 in Healthy Participants

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending ... Read More

Singapore Clinical Trial: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combin... Read More

Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the po... Read More

Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507... Read More

Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More

Pakistan-China cooperation holds huge potential in AI, says Chinese CGPublished on: September 7, 2026 9:56 AM

Pakistan, Sept. 7 -- Consul General of China in Lahore Sun Yan has said that Artificial Intelligence (AI) is not merely a technological revolution but a transformative force that will reshape educatio... Read More

Strong economy, advanced tech vital for national defence: AhsanPublished on: September 7, 2026 9:56 AM

Pakistan, Sept. 7 -- Federal Minister for Planning, Development and Special Initiatives Professor Ahsan Iqbal on Sunday said that Pakistan's defence in the 21st century could no longer be viewed merel... Read More

India's cities need more connections, not just more roads

India, Sept. 7 -- Google Maps says it will take 30 minutes to drive to a place that is barely 10 minutes away as the crow flies. The reason is often not the distance, but the road network: the direct ... Read More

• ««
• «
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• »
• »»